文献速递浆细胞疾病

如何治疗骨髓瘤首次复发

How I treat first relapse of myeloma.
PubMed 文献 · Blood · 2017-07-05

文章讨论了适合患者的骨髓瘤首次复发的治疗选择。标准方案为来那度胺-地塞米松(RD)或硼替佐米-地塞米松(VD),但新型药物的三联方案在缓解率和无进展生存期(PFS)上优于双药方案。达雷妥尤单抗被视为突破性药物,基于其的联合方案可能成为未来首选。作者基于来那度胺/硼替佐米耐药、达雷妥尤单抗可及性和费用提出了决策算法。

要点

  • 来那度胺/硼替佐米耐药、达雷妥尤单抗可及性与费用是首次复发方案选择的关键。
  • 达雷妥尤单抗被视为突破性药物,其联合方案可能成为未来首选。
  • 年轻患者若前期未移植,应考虑自体移植。

核心结论

  • 达雷妥尤单抗是明显的突破性药物,基于达雷妥尤单抗的联合方案可能在不久的将来成为首选选择。
  • 作者提出适合患者首次复发的决策算法,目标是实现最佳PFS,选择基于来那度胺/硼替佐米耐药、达雷妥尤单抗可及性和费用。
  • 年轻患者若前期未使用自体移植,应考虑自体移植。

研究设计与样本

  • 本文为综述,讨论骨髓瘤首次复发的治疗。

主要发现

  • 近期随机研究表明,将新型药物(除泊马度胺外)之一加入RD或VD方案组成的三联方案,在缓解率和无进展生存期(PFS)方面优于双药方案。
  • 来那度胺和硼替佐米目前用于一线治疗,许多患者在疾病早期即对这些药物耐药。
  • 近期开发了6种二线新型药物:泊马度胺、卡非佐米、伊沙佐米、帕比司他、埃罗妥珠单抗和达雷妥尤单抗。

关键数值与推荐

  • 标准治疗为来那度胺-地塞米松(RD)或硼替佐米-地塞米松(VD)。
  • 三联方案在缓解率和PFS上优于双药方案。

临床怎么用

  • 所有新型药物均昂贵,并非所有国家都可获得或负担得起。
  • 作者提出适合患者首次复发的决策算法,目标是实现最佳PFS。

局限性

  • 所有新型药物均昂贵,并非所有国家都可获得或负担得起。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The standard treatment of relapsed multiple myeloma has been either lenalidomide-dexamethasone (RD) or bortezomib-dexamethasone (VD) but it is changing rapidly for 2 reasons. First, lenalidomide and bortezomib are currently used in frontline treatment and many patients become resistant to these agents early in the course of their disease. Second, 6 second-line new agents have been recently developed and offer new possibilities (pomalidomide, carfilzomib and ixazomib, panobinostat, elotuzumab, and daratumumab). Recent randomized studies have shown that triple combinations adding 1 of these new agents (except pomalidomide) to the RD or VD regimens were superior to the double combinations in terms of response rate and progression-free survival (PFS). Their place in the treatment of first relapse is discussed here. Among these agents, daratumumab is clearly a breakthrough and daratumumab-based combinations might become the preferred option in the near future. However, all of these drugs are expensive and are not available or affordable in all countries. We propose a decision algorithm for first relapse in fit patients with the objective of achieving the best PFS. The choice of salvage regimen is based on lenalidomide/bortezomib resistance, daratumumab availability, and cost. Autologous transplantation should be considered in younger patients if not used upfront.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Harousseau JL, Attal M. How I treat first relapse of myeloma. Blood. 2017. PMID: 28679737. doi:10.1182/blood-2017-03-726703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。